Read the latest reports, briefs, and resources from I-MAK:
The critical role of civil society in shaping the market for antiretroviral therapy and direct-acting antivirals
Civil society – in particular people living with and affected by HIV/AIDS – helped shape the market for antiretroviral drugs in low- and middle-income countries. There is a critical need to support civil society interventions that will similarly impact treatment access for hepatitis C.
The HIV Drug Pipeline and its Patents
The Roadmap is intended to help expand access to the next generation of life-saving ARVs in multiple ways. The pages that follow summarize clinical, cost, and legal/patent information around key pipeline drugs for HIV/AIDS.
HIV Drug Patents in China
Data from HIV Chinese Patent Landscape Report.
Hepatitis C
Data from Patent Landscape Report for Pegylated Interferon Alfa 2A & 2B
Tuberculosis Patent Landscapes
Bedaquiline (TMC 207), Delamanid (OPC 67683), SQ-109, AZD 5847, PNU-100480 and PA 824
Patent Landscape Report For Pegylated Interferon Alfa 2A & 2B
Secondary Patenting of Branded Pharmaceuticals: A Case Study of How Patents on Two HIV Drugs Could Be Extended for Decades
T Amin and AS Kesselheim Health Aff 2012 Oct;31(10):2286-94. doi: 10.1377/hlthaff.2012.0107. Abstract Pharmaceutical manufacturers rely on patents to protect their intellectual property and often seek to extend market exclusivity for their products to maximize their return on investment. One method is by obtaining patents on features other than the original active drug ingredient, including secondary…
Voluntary Licensing: Optimizing Global Efforts And Measuring Impact, I-MAK/ITPC
For the past decade, pharmaceutical companies have increasingly used voluntary licenses to allow generic production of patented antiretroviral drugs for People Living with HIV/AIDS in poor countries. However, these licenses have not been pursued optimally from a public health standpoint. This paper will comment on the current efforts of global health institutions and propose a…
Challenges To India’s Pharmaceutical Patent Laws, Science Policy Forum
Evaluating The Potential Impact Of Aurobindo’s Unbundling
Examination of the potential benefit, if any, of Aurobindo’s decision to opt out of the MPP-Gilead license for TDF.
Learn more about how you can help build a more equitable system for all